Common Stock, par value $0.01 per share
- Symbol
- CVM
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07 · 8-K
Cel-Sci Corporation
CVMNYSE_AMERICANEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Securities Holders. The annual meeting of CEL-SCI’s shareholders was held on August 14, 2026. At the meeting the following persons were elected as directors for the upcoming year:…
Company context
We are a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. We are currently focused on the development of the following product candidates and technologies with emphasis on Multikine:
Current securities
Historical securities (1)
Registered securities in this filing
CEL-SCI CORPORATION · 8-K · Filed 2026-08-17
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07. Submission of Matters to a Vote of Securities Holders.
The annual meeting of CEL-SCI’s shareholders was held on August 14, 2026. At the meeting the following persons were elected as directors for the upcoming year:
Name Votes For Votes Withheld Broker Non-Votes
──────────────────────────────────────────────────────────────────────────────
Geert Kersten 4,371,909 478,675 4,365,596
Bruno Baillavoine 2,188,254 2,662,330 4,365,596
Robert Watson 2,062,150 2,788,434 4,365,596
At the meeting the following were approved by CEL-SCI’s shareholders:
(2) the adoption of CEL-SCI’s 2026 Non-Qualified Stock Option Plan; and
(3) the adoption of CEL-SCI’s 2026 Stock Bonus Plan;
(4) to approve, on a non-binding advisory basis, the compensation of CEL-SCI’s executive officers;
(5) to approve, on a non-binding advisory basis, the frequency of the advisory vote regarding the compensation of CEL-SCI’s executive officers; and
(6) to ratify the appointment of BDO USA, LLP as CEL-SCI’s independent registered public accounting firm for the fiscal year ending September 30, 2026; and
The following is a tabulation of votes cast with respect to proposals 2, 3, 4 and 6:
Proposal Votes For Votes Against Abstain Broker Non-Votes
─────────────────────────────────────────────────────────────────────────────────
(2) 3,654,395 1,144,219 51,970 4,365,596
(3) 3,793,843 997,808 58,933 4,365,596
(4) 3,777,031 1,010,124 63,429 4,365,596
(6) 8,638,163 364,150 213,867 0
The following is a tabulation of votes cast with respect to proposals 5:
Proposal 1 Year 2 Years 3 Years Abstain Broker
Non-Votes
───────────────────────────────────────────────────────────────────────────────────
(5) 1,692,789 158,296 2,668,661 330,838 4,365,596